Sartorius Opens Competence Center for Cell and Gene Therapy in Freiburg

Sartorius AG has inaugurated a new competence center in Freiburg, Germany, focusing on cell and gene therapy components. This facility aims to address the growing demand in the biopharmaceutical industry. The company has invested over 140 million euros, significantly increasing its capacity for producing critical materials such as cytokines and growth factors.

The new site spans approximately 18,000 square meters and can house up to 180 employees. It features advanced technologies, including geothermal energy and solar panels, allowing operations without fossil fuels. This commitment to sustainability has earned the site a Gold pre-certification from the German Sustainable Building Council.

This expansion comes as part of Sartorius's long-term strategy to enhance its global research and manufacturing network, following its acquisition of CellGenix GmbH in 2021. By doubling its capacity, Sartorius aims to support the rapid advancement of cell and gene therapies, which already comprise 30% of drug development pipelines.